EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer

Jin-Young Kim, Jeeho Kim, In-Youb Chang, Sang-Gon Park, Ho Jin You, Young Jin Jeon iD, Jung-Hee Lee

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311621 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jin-Young Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Genomic Instability and Cancer Therapeutics, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea. Hauptthemen laut MEDLINE: Piperazines, Phthalazines, Recombinational DNA Repair, Breast Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While PARP inhibitors like Olaparib are effective against BRCA1-deficient breast cancers, their efficacy in BRCA1-proficient tumors depends on the functional status of homologous recombination (HR) repair. Here, we identify the structure-specific endonuclease SLX1 as a key regulator of HR and a determinant of Olaparib sensitivity in BRCA1-intact breast cancer. SLX1 is frequently upregulated in breast cancer and associated with poor prognosis. Functional studies revealed that SLX1 promotes RAD51-mediated HR repair of DNA double-strand breaks. Consequently, SLX1 depletion reduces HR efficiency, increases chromosomal instability, and sensitizes breast-proficient breast cancer cells to DNA-damaging agents, including camptothecin, ionizing radiation, and Olaparib. In contrast, SLX1 overexpression enhances DNA repair capacity and promotes Olaparib resistance. In vivo, SLX1 knockdown synergizes with Olaparib to suppress tumor growth in xenograft models. These findings establish SLX1 as a critical regulator of HR function in BRCA1-proficient breast cancer and a promising target for restoring PARP inhibitor sensitivity through induced HR deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPhthalazinesRecombinational DNA RepairBreast NeoplasmsHumansFemaleAnimalsMiceCell Line, TumorPoly(ADP-ribose) Polymerase InhibitorsDrug Resistance, NeoplasmXenograft Model Antitumor AssaysBRCA1 ProteinDNA Breaks, Double-Stranded

Stichwörter der Autor:innen

PARP inhibitorsSLX1breast cancerhomologous recombination (HR) repair

Substanzen

olaparibPiperazinesPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsBRCA1 Protein

Autor:innen und Institutionen

  • Laboratory of Genomic Instability and Cancer Therapeutics, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
  • Department of Cellular and Molecular Medicine, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
  • Department of Pharmacology, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
  • Department of Anatomy, Chosun University School of Medicine, 375 Seosuk-dong, Gwangju 61452, Republic of Korea.
  • Department of Hemato-Oncology, Chosun University Hospital Internal Medicine, Gwangju 61453, Republic of Korea.

ORCID-Profile: Young Jin Jeon

Förderung

  • National Research Foundation of Korea
  • Ministry of Science

Zitieren

APA

Kim, J. Y., Kim, J., Chang, I. Y., Park, S. G., You, H. J., Jeon, Y. J., & Lee, J. H. (2025). SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311621

Vancouver

Kim JY, Kim J, Chang IY, Park SG, You HJ, Jeon YJ, et al. SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311621

BibTeX
@article{Kim2025,
  author = {Kim, Jin-Young and Kim, Jeeho and Chang, In-Youb and Park, Sang-Gon and You, Ho Jin and Jeon, Young Jin and Lee, Jung-Hee},
  title = {SLX1 Inhibition Enhances Olaparib Sensitivity by Impairing Homologous Recombination Repair in Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311621}
}
Kostenlos starten →